Status:
COMPLETED
Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk
Lead Sponsor:
VA Office of Research and Development
Collaborating Sponsors:
Joslin Diabetes Center
Conditions:
Atherosclerosis
Cardiovascular Disease
Eligibility:
All Genders
21-75 years
Phase:
PHASE2
PHASE3
Brief Summary
The hypothesis is that salsalate therapy may be an effective and safe method to modulate inflammation in metabolically-critical tissues and thus reduce insulin resistance and its related complications...
Detailed Description
Recent studies demonstrate an important role for sub-acute, chronic inflammation in the development of insulin resistance, type 2 diabetes mellitus (T2 DM) and cardiovascular disease (CVD). A broad bo...
Eligibility Criteria
Inclusion
- Male and female veterans between the age of 21-75 who have IFG (impaired fasting glucose) and/or IGT
Exclusion
- any diabetes therapy in the prior 12-months period
- any acute illness
- Ongoing high dose aspirin or Salsalate Therapy
- history of GI bleeding
- hearing problems
- poor vascular access, prior pancreatitis, uncontrolled hypertension, pregnancy, renal disease or anemia
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT00330733
Start Date
January 1 2007
End Date
September 1 2010
Last Update
January 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Carl T. Hayden VA Medical Center
Phoenix, Arizona, United States, 85012